NCT05083169 2026-04-13MajesTEC-3Janssen Research & Development, LLCPhase 3 Active not recruiting587 enrolled 2 FDA
NCT03652064 2026-04-08A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial TherapyJanssen Research & Development, LLCPhase 3 Active not recruiting395 enrolled 11 charts 3 FDA